Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Executive Editor, Commercial/R&D
UK
24+ years of experience
Generics Bulletin
By Aidan Fry 27 Nov 2020
Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.
Topic Biosimilars Deals
Generics Bulletin
By Aidan Fry 27 Nov 2020
California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.
Generics Bulletin
By Aidan Fry 11 Dec 2019
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
Topic Regulation
Generics Bulletin
By Aidan Fry 06 Dec 2019
US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.
Generics Bulletin
By Aidan Fry 20 Nov 2019
In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.
Topic Business Strategies
Generics Bulletin
By Aidan Fry 20 Nov 2019
Accord Healthcare has secured commercial rights to Adienne’s novel lyophilized formulation of thiotepa in Europe, extending its portfolio of cancer treatments.
Topic Business Strategies Cancer
Generics Bulletin
By Aidan Fry 01 Nov 2019
By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.
Generics Bulletin
By Aidan Fry 15 Aug 2019
By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.
Topic Business Strategies
Generics Bulletin
By Aidan Fry 09 Aug 2019
With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.
Topic Business Strategies
Generics Bulletin
By Aidan Fry 22 Mar 2019
Abraxis’ attempt to obtain a UK SPC for its Abraxane formulation of the known active ingredient paclitaxel has been thwarted by the CJEU.
Topic BioPharmaceutical
